MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ecco-jcc/jjag125

Медицинская библиотека · Journal of Crohn's & colitis · 2026

Upadacitinib treatment in pediatric Crohn's disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN.

Spencer Elizabeth A, Cohen Shlomi, Dubinsky Marla C, Suskind David L, Mitrova Katarina, Hradsky Ondrej, Conrad Máire A, Kelsen Judith R, Sladek Malgorzata, Yeh Pai-Jui, Tzivinikos Christos, Henderson Paul, Wlazlo Magdalena, Hackl Lukas, Shouval Dror S, Mouratidou Natalia, Bramuzzo Matteo, Urlep Darja, Olbjørn Christine, D'Orsi Miriam, Schneider Anna-Maria, Pujol-Muncunill Gemma, Gotesdyner Leora, Kang Ben, Gasparetto Marco, Rungø Christine, Romano Claudio, Miele Erasmo, Kolho Kaija-Leena, Hojsak Iva, Norsa Lorenzo, Rinawi Firas, Sansotta Naire, Magen Rimon Ramit, Granot Maya, Scarallo Luca, Trindade Eunice, Velasco Rodríguez-Belvís Marta, Turner Dan, Yerushalmy-Feler Anat

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Data on upadacitinib maintenance therapy in pediatric Crohn's disease (CD) are scarce. We aimed to evaluate the effectiveness, safety, and dosing of upadacitinib as maintenance therapy in pediatric CD.

METHODS

Children treated with upadacitinib for maintenance of remission of active CD from 35 centers affiliated with the Porto Group of ESPGHAN were included in this retrospective cohort study. Data on demographic, clinical, laboratory, endoscopic, and imaging findings and on adverse events (AEs) were recorded over 52 weeks of follow-up.

RESULTS

A total of 120 children were included (91 receiving upadacitinib as monotherapy and 29 as combination advanced therapy, mean age 15.4 ± 2.5 years). Prior to upadacitinib induction, 119/120 (99%) children had been treated with biologic therapies, 104 (87%) with two or more biologics and 98 (82%) had failed both vedolizumab and ustekinumab. Clinical remission and corticosteroid-free clinical remission (CFR) were observed after upadacitinib induction in 77 (64%) and 72 (60%) children, respectively. By week 52, 74 (62%) children achieved both clinical remission and CFR, and CFR was sustained in 66 (55%) children. CFR with normal C-reactive protein levels was achieved in 50% of children and CFR with fecal calprotectin levels <150 µg/g was achieved in 33% of children by week 52. Fifty-three (44%) children sustained AEs, two of which were serious (severe acne and intestinal perforation). The most frequent AEs were acne (n = 23), hyperlipidemia (n = 18), and infections (n = 14).

CONCLUSION

Upadacitinib is an effective maintenance therapy for refractory pediatric CD. Effectiveness should be weighed against the potential risks of AEs.

Для цитирования: Spencer Elizabeth A, Cohen Shlomi, Dubinsky Marla C, Suskind David L, Mitrova Katarina, Hradsky Ondrej, Conrad Máire A, Kelsen Judith R, Sladek Malgorzata, Yeh Pai-Jui, Tzivinikos Christos, Henderson Paul, Wlazlo Magdalena, Hackl Lukas, Shouval Dror S, Mouratidou Natalia, Bramuzzo Matteo, Urlep Darja, Olbjørn Christine, D'Orsi Miriam, Schneider Anna-Maria, Pujol-Muncunill Gemma, Gotesdyner Leora, Kang Ben, Gasparetto Marco, Rungø Christine, Romano Claudio, Miele Erasmo, Kolho Kaija-Leena, Hojsak Iva, Norsa Lorenzo, Rinawi Firas, Sansotta Naire, Magen Rimon Ramit, Granot Maya, Scarallo Luca, Trindade Eunice, Velasco Rodríguez-Belvís Marta, Turner Dan, Yerushalmy-Feler Anat. Upadacitinib treatment in pediatric Crohn's disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN.. Journal of Crohn's & colitis. 2026. DOI: 10.1093/ecco-jcc/jjag125.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.